AACR logo

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Abstract C062: The use of nanoparticles to improve tumour radiosensitivity
Ben Reed, Gareth Wakefield, Matt Stock, Gregory Tudor

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C062; DOI: 10.1158/1535-7163.TARG-19-C062
Abstract C050: A novel, potent, and selective hypoxia-inducible factor (HIF)-2α antagonist
Kelsey E Sivick Gauthier, Kenneth V Lawson, Dana Piovesan, Matthew J Walters, Ada Chen, Xiaoning Zhao, Cesar Meleza, Nikki Kimura, Tim Park, Steve Young, Anh Tran, Samuel L Drew, Lixia Jin, Manmohan Leleti, Elaine Ginn, Jay P Powers

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C050; DOI: 10.1158/1535-7163.TARG-19-C050
Abstract C056: MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab
Fredrik G Oberg, Karin Tunblad, Ana Slipicevic, Richard Bethell, Mark R Albertella

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C056; DOI: 10.1158/1535-7163.TARG-19-C056
Abstract C043: Targeting TXNRD1 with a competitive inhibitor exposes an Achilles heel of SCLC
Nikolas Peter Gunkel, Eberhard Amtmann, Pjotr Fabrowski, Sanaz Taromi, Tobias Dick

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C043; DOI: 10.1158/1535-7163.TARG-19-C043
Abstract C042: Inhibition of Dihydroorotate Dehydrogenase (DHODH) by RP7214 attenuates growth and promotes differentiation of AML cell lines
Srikant Viswanadha, Satyanarayana Eleswarapu, Swaroop Vakkalanka

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C042; DOI: 10.1158/1535-7163.TARG-19-C042
Abstract C054: Discovery of KYM-003, a potent and selective STAT3 degrader with antitumor activity in heme malignancies
Fred Csibi, Nan Ji, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, Scott Rusin, Kirti Sharma, Christine Loh, Henry Li, Sharon Townson, Hari Kamadurai, Jesse Chen, Duncan Walker, Jared Gollob, Nello Mainolfi

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C054; DOI: 10.1158/1535-7163.TARG-19-C054
Abstract C049: Identification of novel K-Ras G12C inhibitors using a DNA encoded library platform
Shilpi Arora, Chris Hupp, Sarah Talcott, Usha Narayanan, Diana Gikunju, Mortiz Von Rechenberg, Michael I Monteiro, John P Giulinger, Kyle Denton, Matt Clark, Andrew Ferguson, Andrew J McRiner, John Cuozzo, Christelle Huguet, Anthony D Keefe

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C049; DOI: 10.1158/1535-7163.TARG-19-C049
Abstract LB-A15: IACS-010759 is a novel inhibitor of oxidative phosphorylation that selectively targets AML cells by inducing a metabolic catastrophe
Jennifer R. Molina, Marina Protopopova, Madhavi Bandi, Jennifer Bardenhagen, Christopher Bristow, Maria Alimova, Christopher Carroll, Edward Chang, Ningping Feng, Jason Gay, Mary Geck Do, Jennifer Greer, Sha Huang, Yongying Jiang, Marina Konopleva, Polina Matre, Zhijun Kang, Gang Liu, Timothy McAfoos, Pietro Morlacchi, Melinda Smith, Sonal Sonal, Jay Theroff, Quanyun Xu, Giulio Draetta, Philip Jones, Carlo Toniatti, M. Emilia Di Francesco, Joseph R. Marszalek

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) LB-A15; DOI: 10.1158/1535-7163.TARG-15-LB-A15
Abstract LB-A17: Hospital volume determines mortality amongst neutropenic cancer patients within the United States
Yaacov Richard Lawrence, Damian Urban, Tal Sella, Jair Bar, Raanan Berger, Jeffrey Goldstein, Einat Shacham-Shmueli, Zvi Symon, Talia Golan

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) LB-A17; DOI: 10.1158/1535-7163.TARG-15-LB-A17
Abstract LB-A19: Ceramide-Rubusoside, an Ultrasmall Nanomicells Effectively Restores p53 Expression in the Missense Mutant Cancer Cells
Yong-Yu Liu, Zhijun Liu, Sachin K. Khiste, Salman B. Hosain

Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) LB-A19; DOI: 10.1158/1535-7163.TARG-15-LB-A19

Main menu

User menu

Search

More articles from Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT